DDInter909 DDInter899
Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated with a daily dosage of 300 mg or more and typically occurred in the first four weeks of therapy".. The discovery of imatinib also established a new group of therapy called "targeted therapy", since treatment can be tailored specifically to the unique cancer genetics of each patient. Imatinib was approved on February 1st,2001 by the FDA and November 7th, 2001 by the EMA; however, its European approval has been withdrawn in October 2023.[A263036,L49746,L49751]
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.
Imatinib {u} (Compound) resembles {v} (Compound) Buclizine
Imatinib {u} (Compound) treats {v} (Disease) hematologic cancer
Imatinib {u} (Compound) binds {v} (Gene) CA12
Imatinib {u} (Compound) upregulates {v} (Gene) MEF2C
Imatinib {u} (Compound) downregulates {v} (Gene) DECR1
Imatinib {u} (Compound) causes {v} (Side Effect) Eye disorder
Imatinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Dolutegravir
Imatinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Citalopram
Imatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ixabepilone
Imatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alemtuzumab
Imatinib (Compound) resembles Buclizine (Compound)
Imatinib (Compound) treats hematologic cancer (Disease)
Imatinib (Compound) binds CA12 (Gene)
Imatinib (Compound) upregulates MEF2C (Gene)
Imatinib (Compound) downregulates DECR1 (Gene)
Imatinib (Compound) causes Eye disorder (Side Effect)
Imatinib may cause a minor interaction that can limit clinical effects when taken with Dolutegravir
Imatinib may cause a minor interaction that can limit clinical effects when taken with Citalopram
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Ixabepilone
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzumab